Symphonix Vibrant Soundbridge Claims Should Reflect Data Subjectivity
This article was originally published in The Gray Sheet
Executive Summary
Labeling claims should reflect the subjective nature of data obtained from clinical studies supporting FDA approval of Symphonix Devices' Vibrant P and Vibrant D "Soundbridge" implant hearing system, FDA's Ear, Nose and Throat Devices Panel concluded at a July 20 meeting in Gaithersburg, Maryland.
You may also be interested in...
Implantable Middle Ear Hearing Device Control Comparison Weighed By CDRH
FDA will need to decide whether a planned guidance on implantable middle ear hearing devices should allow sponsors to control against unaided conditions
Implantable Middle Ear Hearing Device Control Comparison Weighed By CDRH
FDA will need to decide whether a planned guidance on implantable middle ear hearing devices should allow sponsors to control against unaided conditions
Symphonix Plans Vibrant SoundBridge Postmarket Surveillance Study
Symphonix Devices will conduct an 18-month postmarket surveillance study of patients implanted with the Vibrant P and Vibrant D Soundbridge implantable middle-ear hearing devices. FDA approved the products on Aug. 31.